(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — En la lucha contra el virus SARS-CoV-2, una gran cantidad de empresas farmacéuticas están buscando nuevos enfoques para combatir la pandemia. Además de las vacunas, las iniciativas exhaustivas de investigación y … Read the full press release
Posted in Austria, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science, Spain
Tagged aerosoles nasales, anti-SARS-CoV-2, antihistamínico azelastine, azelastine, biotecnología, CEBINA, colaboración, COVID-19 medication, COVID-19 treatment, fármaco antihistamínico clorhidrato de azelastina, medicamento antialérgico Pollival, nuevas terapias anti-COVID, pandemia, profesor Dr.Ferenc Jakab, profesor Dr.Robert Konrat, readaptación de medicamentos, SARS-CoV-2, Sophie Zettl, URSAPHARM Arzneimittel
(PRESS RELEASE) SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EuropaWire/ — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts … Read the full press release
Posted in Austria, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science
Tagged anti-allergic medication Pollival, anti-COVID therapeutics, antihistamine drug, antiviral properties, azelastine, azelastine hydrochloride, CEBINA GmbH, Central European Biotech Incubator and Accelerator, clinical trial, COVID-19, COVID-19 medication, Covid-19 pandemic, COVID-19 treatment, nasal spray, ophthalmology, Pollival, Prof Dr Robert Konrat, Prof Dr. Ferenc Jakab, re-purpose drugs, SARS-CoV-2, Sophie Zettl, University of Pécs, University of Vienna, URSAPHARM Arzneimittel GmbH, viral spread
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release
Posted in Banks, European Union, Financial, France, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Small Business
Tagged 3CL protease, AB Science SA, Alain Moussy, Ambroise Fayolle, anti-inflammatory, antiviral, chemotherapy, COVID-19, COVID-19 treatment, EIB, European Commission, European Fund for Strategic Investments, European Investment Bank, European Union, financing, health crisis, Horizon 2020, immunotherapeutic, inflammatory disease, innovationm, InnovFin, investments, kinase inhibitors, kinases, loan, macrophages, masitinib, microglia, neurological diseases, oncology, PKIs, RESEARCH, SARS-CoV-2, tyrosine kinase inhibitor
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
